INFLAMMATORY BREAST CANCER INTERNATIONAL CONSORTIUM (EIN 463393042) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2013

Legal Domicile

Principal Officer

MASSIMO CRISTOFANILLIMD

Phone

2483903027

Tax Period

2023-01-01 to 2023-12-31

INFLAMMATORY BREAST CANCER INTERNATIONAL CONSORTIUM, founded in 2013, is a micro nonprofit in the Diseases & Disorders sector that reported $69K in total revenue in fiscal year 2023. Revenue surged 715% from the prior year, signaling strong growth momentum. Expenses of $61K left a modest 12% surplus.

Mission

TO BRING ABOUT LIFESAVING BREAKTHROUGHS FOR THOSE AFFECTED BY INFLAMMATORY BREAST CANCER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $68,948

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $68,948

Expense Breakdown

Grants Paid $60,000

Salaries & Benefits $0

Fundraising Expenses $109

Program Expenses $60,634

Other Expenses $905

TOTAL EXPENSES $60,905

Year-over-Year Comparison

	2023	2022	Change
Revenue	$68,948	$8,455	+7.2%
Expenses	$60,905	$26,588	+1.3%
Net Income	$8,043	$-18,133	-1.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MASSIMO CRISTOFANILLI	PRESIDENT	20.00	Officer Director	$0	$0	$0
KENNETH VAN GOLEN	VICE-PRESIDENT/TREASURER	5.00	Officer Director	$0	$0	$0
VALERIE FRASER	SECRETARY	20.00	Officer Director	$0	$0	$0
LUC DIRIX	DIRECTOR	5.00	Director	$0	$0	$0
STEVEN VAN LAERE	DIRECTOR	5.00	Director	$0	$0	$0
FILIPA LYNCE	DIRECTOR	5.00	Director	$0	$0	$0
BORA LIM	DIRECTOR	5.00	Director	$0	$0	$0
PAUL LEVINE	DIRECTOR	5.00	Director	$0	$0	$0
SOFIA MERAJVER	DIRECTOR	5.00	Director	$0	$0	$0
HAMOUDA BOUSSEN	DIRECTOR	5.00	Director	$0	$0	$0
PATRICE VIENS	DIRECTOR	5.00	Director	$0	$0	$0
LAURA PENA	DIRECTOR	5.00	Director	$0	$0	$0
FREDIKA ROBERTSON	DIRECTOR	5.00	Director	$0	$0	$0
GAYATHRI DEVI	DIRECTOR	5.00	Director	$0	$0	$0
AMR SOLIVAN	DIRECTOR	5.00	Director	$0	$0	$0
LISA NEWMAN	DIRECTOR	5.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$68,948	$60,905	$172,958	$8,043
2022	$8,455	$26,588	$164,915	$-18,133
2021	$147,493	$95	$183,048	$147,398

INFLAMMATORY BREAST CANCER INTERNATIONAL CONSORTIUM